Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Johns Hopkins Researchers to Evaluate Malaria Saliva Test

by Global Biodefense Staff
March 11, 2015
NAMRU-6 Malaria

Researchers at the Johns Hopkins Bloomberg School of Public Health have been awarded a $525,000 grant from the Bill & Melinda Gates Foundation to evaluate a promising technology that detects malaria parasites in saliva before individuals get sick and become carriers of the parasite.

The team, part of the Johns Hopkins Malaria Research Institute, will work with the biotech firm Ceres Nanosciences to assess a sampling platform developed by Ceres.

Despite progress in the campaign to eliminate the mosquito-borne illness, malaria still sickens an estimated 200 million people a year and kills an estimated 600,000 of them, mostly children under the age of five.

Non-invasive tests that do not require needles or lab work — the way many blood tests do — and can provide rapid diagnosis are seen as a critical step in reducing first-time malaria cases and blocking transmission by those who have recovered but still carry the parasite. Malaria is most successfully treated when caught early.

Preliminary research suggests there is a new set of malaria biomarkers present in saliva, which could identify a larger population of malaria carriers than previously estimated. The Ceres test uses its Nanotrap particle technology to sample and enrich saliva to identify the presence of the malaria biomarker.

During a six-month evaluation, the Hopkins team will work with Ceres to evaluate whether the biomarker can increase the percentage of asymptomatic carriers of malaria who can be correctly diagnosed.

In their assessment, researchers will compare the concentration of biomarkers in blood and saliva and also between symptomatic and asymptomatic carriers. A variation of this test could also be used to diagnose first-time malaria cases. The test would thus lead to faster treatment for those cases as well as stave transmission.

“This platform could present a very compelling solution for rapid identification of infected individuals who may otherwise go undetected,” says Rhoel Dinglasan, PhD, the principal investigator and an assistant professor in the Bloomberg School’s Department of Molecular Microbiology and Immunology. “If the test proves effective, it could meet an unmet public health need, and fill a critical gap in our knowledge by enabling the identification of asymptomatic individuals who contribute to malaria transmission.”

An inexpensive rapid diagnostic test could be used to assess children and adults in large-scale screenings in settings such as schools and community centers. Those who tested positive would receive antimalarials, which could greatly reduce an infection source.

Ceres’ Nanotrap technology was invented at George Mason University with funding from the National Institutes of Health (NIH), and currently is being developed into commercial products by Ceres with continuing support from NIH and other agencies.

The grant period began last month and will run through the summer.

Tags: AwardsBiomarkersMalariaMosquito-Borne

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC